Age versus clinical virological characteristics in chronic hepatitis B virus inf

StephenW

Eur J Gastroenterol Hepatol. 2012 Jan 23.
Source: http://www.ncbi.nlm.nih.gov/pubmed/22273989
Age versus clinical virological characteristics in chronic hepatitis B
virus infection: a case series study in China. Wu DL, Xu GH, Lu SM, Ma BL,
Miao NZ, Liu XB, Feng JH, Liu N, Zeng QL, Hou WK, Pei L, Zhao Y.
SourceaDepartment of Genetics and Molecular Biology, School of Medicine
bKey Laboratory of Environment and Genes Related Diseases of Ministry of
Education cDepartment of Epidemiology and Health Statistics, School of
Public Health dDepartment of Infectious Diseases, First Affiliated Hospital
of Medical College, Xi'an Jiaotong University, Xi'an eDepartment of
Infectious Diseases, Affiliated Hospital of Yan'an University fMedical
College of Yan'an University, Yan'an, Shaanxi Province, China.

Abstract
OBJECTIVES: This study aimed to investigate the clinical virological
characteristics of hepatitis B virus (HBV) in chronic HBV infection
patients of different ages, especially in relapse patients and patients
with immune clearance. METHODS: The HBV clinical virological
characteristics of chronic HBV infection were investigated in 1572 Chinese
patients of different age groups (<20, 20-40, and >40 years old). RESULTS:
Of the patients in the below 20 age group, those with evidence of immune
tolerance accounted for 86.05% (P<0.001). Of the patients in the 20-40 age
group, those with immune clearance accounted for 36.36% (P<0.001). Of the
patients in the above 40 age group, there were markedly more reactivation
cases than in any other group (P<0.001). Our data indicated that a positive
correlation (r=0.480, P<0.001) existed between HBV DNA contents (on a
log10 scale) and the alanine aminotransferase (ALT) level of the total
cases with reactivation. Of the 300 cases with immune clearance being
followed up 10-50 months after enrollment, 181 cases achieved spontaneous
hepatitis B e antigen (HBeAg) seroconversion (HBeAg to anti-HBe), and the
younger the patient, the shorter the time to seroconversion (P<0.05).
CONCLUSION: Generally, there were significantly different HBV clinical
virological characteristics in patients with chronic HBV infection of
different ages. Different features were observed in relapse patients and
patients with immune clearance at different ages, and these two types of
patients needed antiretroviral therapy. Our study suggests that revisions
of the timing and elevated alanine aminotransferase standards for chronic
hepatitis B antiretroviral therapy in Chinese relapse patients and patients
with immune clearance in different age groups are warranted.

StephenW

Europe胃肠肝胆病。 2012年1月23日。
资料来源：http://www.ncbi.nlm.nih.gov/pubmed/22273989
年龄与慢性乙型肝炎临床病毒学特征
病毒感染：在中国的系列案例研究。吴赉，徐国华，吕SM，马BL，
苗新元，刘预算外，冯红，刘娜，曾庆红QL，侯WK，裴，赵Y。
SourceaDepartment遗传学和分子生物学，医学院
bKey实验室的环境与基因相关疾病的部
流行病与卫生统计学，学校教育cDepartment
传染病公共卫生dDepartment第一附属医院
医学院，西安交通大学，西安eDepartment
传染病，延安大学fMedical附属医院
学院，中国陕西省延安大学，延安。

摘要
目标：本研究旨在探讨临床病毒学
B型肝炎病毒（HBV）慢性乙肝病毒感染的特点
不同年龄段的患者，尤其是在复发患者和患者
免疫清除。方法：HBV临床病毒学
慢性乙肝病毒感染的特点进行了调查，1572中国
不同年龄组的患者（<20，20-40，和> 40岁）。结果：
在低于20岁年龄组，免疫的证据的患者
宽容占86.05％（P <0.001）。在20-40岁的患者
组，免疫清除的占36.36％（P <0.001）。的
在40岁以上年龄组的患者，有显着更多的激活
的情况下比在任何其他组（P <0.01）。我们的数据表明，积极的
HBV DNA含量之间存在相关性（R = 0.480，P <0.001）（上
LOG10规模）和丙氨酸转氨酶（ALT）总水平
例与激活。免疫清除被300例
其次入学后10-50个月，181例，取得了自发
乙型肝炎e抗原（HBeAg）血清转换（HBeAg的抗- HBe），和
年轻患者，在较短的血清转换时间（P <0.05）。
结论：通常情况下，有显著不同的乙肝临床
在慢性乙肝病毒感染患者的病毒学特征
不同年龄段。不同的特点，观察复发的患者，
在不同年龄段的免疫清除的患者，这两种类型的
患者需要抗逆转录病毒治疗。我们的研究表明，修订
的时机和慢性转氨酶升高丙氨酸标准
乙肝在中国的复发患者和患者的抗逆转录病毒疗法
在不同年龄组的免疫清除是必要的。

咬牙硬挺

什么意思？

StephenW

回复 咬牙硬挺 的帖子

我不知道的细节。基本上，论文说，应修改 a)患者在免疫清除期, b) 患者在复发阶段
1。何时开始治疗，
2。用来指示治疗的ALT水平.

理由:

300例免疫清除患者, 在10-50个月181例，取得了自发 e抗原（HBeAg）血清转换（HBeAg的抗- HBe）;年轻患者，有较短的至血清转换时间（P <0.05）。
[我的理解：如果你还年轻，在免疫清除期，也许你应该推迟治疗, 最有可能的你会取得了自发 e抗原（HBeAg）血清转换]

复发患者, 数据表明，HBV DNA含量(LOG10规模）和 丙氨酸转氨酶（ALT）之间存相关性.
[我不明白这观察的含义]